2-[5-[(Z)-(3-benzyl-4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene)methyl]furan-2-yl]benzoic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-[5-[(Z)-(3-benzyl-4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene)methyl]furan-2-yl]benzoic acid
• 化学式: C₂₂H₁₅NO₄S₂
• 分子量: 421.5
• InChiKey: PNERZDHCXUYCAR-UNOMPAQXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  29
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  128
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• Use of Thiazolidinone Derivatives as Antiangiogenic Agents
  申请人：Cassin Mara

  公开号：US20080261980A1

  公开（公告）日：2008-10-23

  The invention relates to the use of compounds of general formula (I), in which R 1 , R 2 and X are as defined in the description for the preparation of pharmaceutical compositions for the treatment of pathologies in which inhibition of the interaction between HIF-1α and p300 is beneficial, in particular as antiangiogenic medicaments for the therapy of solid tumors.

  本发明涉及使用通式(I)中的化合物，其中R1、R2和X如说明书中所定义，用于制备药物组合物，用于治疗抑制HIF-1α和p300之间相互作用有益的病理情况，特别是作为治疗实体瘤的抗血管生成药物。
• USE OF THIAZOLIDINONE DERIVATIVES AS ANTIANGIOGENIC AGENTS
  申请人：Cell Therapeutics Europe S.R.L.

  公开号：EP1830848A1

  公开（公告）日：2007-09-12
• USE OF THIAZOLIDINONE DERIVATIVES FOR THE TREATMENT OF SOLID TUMORS
  申请人：Cell Therapeutics Europe S.R.L.

  公开号：EP1830848B1

  公开（公告）日：2009-12-16
• [EN] USE OF THIAZOLIDINONE DERIVATIVES AS ANTIANGIOGENIC AGENTS<br/>[FR] UTILISATION DE DERIVES DE THIAZOLIDINONE COMME AGENTS ANTIANGIOGENIQUES
  申请人：CELL THERAPEUTICS EUROPE SRL

  公开号：WO2006066846A1

  公开（公告）日：2006-06-29

  [EN] The invention relates to the use of compounds of general formula (I), in which R₁, R₂ and X are as defined in the description for the preparation of pharmaceutical compositions for the treatment of pathologies in which inhibition of the interaction between HIF-1a and p300 is beneficial, in particular as antiangiogenic medicaments for the therapy of solid tumors.
  [FR] L'invention concerne l'utilisation de composés de formule générale (I), dans laquelle R₁, R₂ et X sont tels que définis dans la description, pour la préparation de compositions pharmaceutiques destinées à traiter des pathologies dans lesquelles une inhibition de l'interaction entre HIF-1a et p300 est bénéfique, en particulier comme médicaments antiangiogéniques en traitement de tumeurs solides.
• [EN] LEUKADHERIN-1 ALONE OR IN COMBINATION FOR USE IN THE TREATMENT OF CANCER<br/>[FR] LEUKADHÉRINE-1 SEULE OU EN ASSOCIATION POUR UNE UTILISATION DANS LE TRAITEMENT DU CANCER
  申请人：GB006 INC

  公开号：WO2020236668A1

  公开（公告）日：2020-11-26

  Disclosed herein are methods for treating cancer by administration to a patient in need thereof, an effective amount of (Z)-4-(5-((3-benzyl-4- oxo-2-thioxothiazolidin-5-ylidene)methyl) furan-2-yl)benzoic acid or pharmaceutically acceptable salts thereof in an amount of about 50 mg to about 1800 mg. In some embodiments, the choline salt of (Z) -4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene) methyl) furan-2-yl) benzoic acid is administered. In some embodiments, the patient has a solid tumor.